(CercleFinance.com) – Nicox shares jumped in volumes on Wednesday on the Paris Stock Exchange after a commercial point on Vyzulta, the treatment against glaucoma developed by the specialist in ophthalmology.
At 11:30 a.m., the stock was up nearly 9% in volumes already representing double those traded over the entire session the day before. At the same time, the Paris market grew by 1.3%.
In a statement released in the morning, Nicox announced that Vyzulta was now marketed in seven territories and approved in nine other countries.
As of December 31, the drug was thus available in the United States, Canada, Argentina, Mexico, Hong Kong, Taiwan and Ukraine.
The compound has also been approved in nine other countries, namely Brazil, Colombia, Jordan, Qatar, Singapore, South Korea, Thailand, Turkey and the United Arab Emirates.
As a reminder, Vyzulta – an ophthalmic solution derived from latanoprostene bunod – is licensed exclusively worldwide to the pharmaceutical laboratory Bausch+Lomb.
Nicox nevertheless retains the patents for the drug, with patents potentially eligible for extension until 2030 in the United States.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
